Streptococcus suis is an emerging zoonotic pathogen. Lacking an effective vaccine, 3 antibiotics remain the main tool to fight against infections caused by these bacteria. We have 4 previously observed a reserpine-sensitive fluoroquinolone-efflux phenotype in this species. 
30
Syndrome (STSS) similar to the one produced by Group A streptococci (GAS) (37). Consequently,
31
concern about this pathogen has risen in these areas, and measures to prevent or hinder its 32 impact are already being taken (18).
33
Antimicrobial resistance is one of the most concerning phenomena in infectious diseases.
34
In S. suis, resistance to neomycin, spiramycin, lincomycin, trimethoprimsulphamethoxazole,
35
erythromycin and tetracycline antibiotics is a common feature (30, 33, 41 
53
Efflux-mediated drug resistance is normally a consequence of overexpression of the genes 54 encoding the pumps, either through mutations in regulators or in promoter regions thereof (28).
55
Amino acid substitutions can also lead to resistance through a change in the substrate recognition 56 of the pump (29, 31).
57
To date, no FQ efflux pumps have been described in S. suis. Here we report the implication 58 of SatAB, an ABC transporter homologous to PatA and PatB, in resistance to ciprofloxacin and 59 norfloxacin in S. suis. Further, intensive study of SmrA, a Major
DNA analysis and manipulation 86
Primers used in this study were supplied by Roche (Roche, Germany), and SigmaGenosys
87
(Sigma Chemical Co. St Louis, Mo). A list of the primers used can be found in Table 2 (Table 2) were designed using Allele ID 7.7 software (Premier Biosoft, Palo Alto, CA). Q-
112
PCR was carried out in triplicates using MyiQ thermal cycler (Bio-Rad Laboratories Inc. Spain).
113
Every condition and strain was tested three times. No primer dimer was obtained in any of the
114
PCRs. Efficiency of all assays was 100% ± 5%. Results on the expression of smrA and satAB were 115 normalized using rpoB. Primers rpoB428 and rpoB468R, targeting the rpoB gen of S. pneumoniae, 116 have been previously described (4).
117
Cloning of smrA and satAB in B. subtilis chromosome 118
In order to clone smrA and satAB in pDR67, XbaI and BglII restriction sites were used.
119
Amplification of the ORFs including their putative RBSs was carried out using primers designed to 120 bear both restriction sites (Table 2) . Plasmid and inserts were digested using XbaI and BglII (Takara 121 Bio, Inc., Japan) and ligated using T4 DNA ligase (New England Biolabs, Beverley, MA). Ligation 122 product was directly transformed in B. subtilis using a two-step transformation procedure as 123 previously described (15). Colonies were phenotypically tested for pDR67 integration in the 124 chromosome. Briefly, amyE disruption leads to the loss of alpha amylase activity. This can be 125 evidenced by growth on 1% potato starch and staining with iodine pearls. Clones not showing a 126 light halo around the colonies were selected, for its amylase activity was lost, presumably because restriction sites located close together and facing outwards ( Table 2 ). The product was 131 phosphorilated using polinucleotide kinase, ligated using T4 DNA ligase and transformed in S.
132 pneumoniae R6 as previously described (23). The resulting plasmid was called pJS3EB and bore
133
both restriction sites plus a new unique NdeI site in between. Pspac-lacI and Pspac-smrA-lacI from 134 strains BB1066 and BB1067 respectively, were amplified using primers with EcoRI and BamHI 135 restriction sites (Table 2) . Both inserts and pJS3EB were digested using EcoRI and BamHI and 136 ligated with T4 DNA ligase. All enzymes were purchased from New England Biolabs (New England
137
Biolabs, Beverley, MA).
138
Influence of pH in the activity of SmrA 139 LB was used as growth media and pH was adjusted to 5, 6, 7 and 8 adding HCl or NaOH 
147

BIOLOG 148
Biolog phenomic assays were performed at the Veterinary Laboratories Agency,
149
Weybridge, UK. Strains were grown on agar plates under selective pressure as described above.
150
Cell suspensions were prepared as previously described (2) 
175
No decrease in the MIC was observed in any of the FQsusceptible strains in presence of reserpine.
176
To unequivocally prove these results, a diffusion antibiogram method that enabled a clear 
231
Expression analysis 232
Efflux pumps can lead to antimicrobial resistance through overexpression. In order to 
241
Expression of satAB was found to be about fifteen times higher in BB1013 than in the 242 control strain in the absence of ciprofloxacin. Interestingly, expression was not enhanced, but 243 mildly repressed by the presence of ciprofloxacin in the growth media.
244
Expression analysis showed that both pumps were overexpressed in BB1013, either under 245 induction by ciprofloxacin, as is the case of SmrA, or constitutively as for SatAB. Moreover, these 246 data suggest that satR acts as a repressor of satAB in S. suis.
248
Cloning and expression of smrA and satAB in B. subtilis 249
Cloning of satAB and smrA in E. coli, as performed successfully with other pumps such as
250
NorA or Bmr (27, 38), was investigated. All assays were negative when trying to clone the genes 251 encoding the putative pumps in pCR2.1 plasmid and E. coli IncF' strain. Cloning under the control 252 of pBAD promoter was tested. Despite enhanced repression by addition of G-6-P (glucose-6- insert. RT-PCR was performed proving the induction of the system in this strain (data not shown).
288
As MFS transporters obtain their energy from the proton gradient between the periplasm and the 289 cytoplasm, we investigated whether pH of the medium could play a role in the activity of SmrA 290 against fluoroquinolones. Growth curves on LB medium at pH 5, 6, 7 and 8 were performed. 
308
In order to rule out the possibility of SmrA not being active in B. subtilis the construction,
309
from Pspac to lacI (see Figure 5) 
332
This points to the diversity in amino acid composition of the three alleles of SatAB as a possible 333 factor in the levels of resistance through modifications in the affinity for the drug. 
348
Here we present SatAB, an efflux pump involved in fluoroquinolone resistance in S. suis.
349
We also assessed the involvement of SmrA, an MFS transporter homologous to FQ-efflux pump 
382
PmrA is an MFS efflux pump from S. pneumoniae that has been, at least for some time,
383
considered to be the main norfloxacin exporter in this bacterium. Since its first description (12)
384
PmrA has generally failed to be further related to FQ resistance in either wild type strains or pDR67 disrupting amyE, has no amylase activity. Starch is stained and no light zone is visible.
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